QQ客服 官方微博 反馈留言

	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
	Coiffier, Bertrand; Osmanov, Evgenii A.; Hong, Xiaonan; Scheliga, Adriana; Mayer, Jiri; Offner, Fritz; Rule, Simon; Teixeira, Adriana; Walewski, Jan; de Vos, Sven
刊名	LANCET ONCOLOGY
	2011
卷号	12期号:8
ISSN号	1470-2045
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4927610
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Coiffier, Bertrand,Osmanov, Evgenii A.,Hong, Xiaonan,et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial[J]. LANCET ONCOLOGY,2011,12(8).
APA	Coiffier, Bertrand.,Osmanov, Evgenii A..,Hong, Xiaonan.,Scheliga, Adriana.,Mayer, Jiri.,...&Zinzani, Pier Luigi.(2011).Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.LANCET ONCOLOGY,12(8).
MLA	Coiffier, Bertrand,et al."Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial".LANCET ONCOLOGY 12.8(2011).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。